Four former FDA commissioners in a letter sent last week to members of Congress cautioned lawmakers against allowing U.S. patients to import drugs from other countries.
The letter was signed by former FDA Commissioners:
- Robert Califf, who served as commissioner from February 2016 to January 2017;
- Margaret Hamburg, the foreign secretary of the National Academy of Medicine and president-elect of AAAS, who served as commissioner from 2009 to 2015;
- Mark McClellan, director of the Duke-Robert J. Margolis Center for Health Policy at Duke University, who served as commissioner from 2002 through 2004; and
- Andrew Von Eschenbach, senior fellow at the Milken Institute and president of Samaritan Health Initiatives, who served as commissioner from 2006 to 2009.
They wrote that U.S. residents and some members of Congress "have expressed serious concerns about access to and cost of prescription drugs," and while they "share [those] concerns and believe [the United States] need[s] better systems that enable affordable access to life-saving medicines," they do not think that importing drugs from other countries is "the right approach."
The former FDA commissioners cited various concerns with allowing U.S. patients to import drugs from other countries. For instance, the former commissioners wrote that FDA does not have the necessary resources to properly oversee a large drug importation program. They added that imported drugs could be adultered, fake, substandard, or unsafe, and that allowing importation could pose serious risks to consumers and patients.
In addition, the former commissioners wrote that allowing drug importation likely would achieve only minimal cost savings. Further, they wrote that allowing importation ultimately could decrease patients' access to drugs because treatments that are in limited supply would be open to a new influx of patient demand.
The former FDA commissioners suggested policymakers look into alternatives such as tying drugs' prices to their clinical values and streamlining the approval processes for generic and biosimilar drugs. They concluded, "We urge Congress and the many others concerned about the cost of drugs to deal directly with the issues driving the cost of medicines and not to place false hope in measures that will place patients who need treatment at risk and jeopardize public health" (Bean, Becker's Hospital Review, 3/17; McGinley, "To Your Health," Washington Post, 3/17).
Your guide to an optimized retail pharmacy strategy
Building on research presented at the Pharmacy Executive Forum’s 2016 Fall Summit, this web conference will provide guidance for how to develop or update your retail pharmacy strategy.
- Developing the retail pharmacy value proposition
- Targeting high-value patient populations for retail pharmacy growth
- Evaluating potential retail pharmacy partnership opportunities
- Leveraging retail pharmacy to improve clinical outcomes